Ingenovis Health: Still Nursing Losses

Welcome to the 204th Pari Passu newsletter.

In today’s edition, we are covering Ingenovis Health, a healthcare staffing platform brought together by Cornell Capital and Trilantic North America from four independent staffing brands. Formed during the COVID pandemic and amidst the largest staffing demand on record, the combined platform nearly tripled its revenue to over $1.9bn by 2022, while three additional acquisitions extended its reach and brought total debt to $760mm.

Within a year, the demand beneath that structure had broken. Hospitals rebuilt their own workforces, order volume and bill rates fell together, and revenue halved by 2024 while rising rates nearly tripled the company’s interest bill. By early 2026, the company was surviving on maturity extensions measured in weeks. In May 2026, Ingenovis closed a recapitalization supported by 100% of its first lien lenders and funded in part by new money from its sponsors. 

In this write-up, we’ll walk through Ingenovis’s business model, trace the corporate history from the 2021 buyout through the acquisition spree, then break down the path to distress and the initiatives that failed to stop it. We’ll close by examining the 2026 LME, another restructuring from this year after Multi-Color that features a sponsor injection to retain equity through a restructuring. 

Hospitals sell a service that cannot wait. As patient volumes swing with flu seasons, outbreaks, and leaves, wards must be routinely staffed with work that can only be completed by licensed clinicians. At the same time, a hospital cannot reliably size its permanent staff for its busiest weeks without wasting money.  Recruiting, licensing, and credentialing a single nurse takes months, so when a hospital comes up short, its best option is to rent a clinician who is already licensed and ready to work [1]. 

This is where Ingenovis comes in. At its core, Ingenovis is a healthcare staffing agency, recruiting nurses, allied health professionals (clinical workers who are neither doctors nor nurses, such as physical therapists and X-ray technicians), and physicians into its database. It then “rents” them out to hospitals that cannot fill shifts on their own. 

The hospital pays Ingenovis an hourly bill rate, currently in the low-to-mid $90s for a typical travel nurse, and Ingenovis pays the nurse an hourly rate plus tax-free housing and travel stipends [1]. The company earns the difference between the two, known as the bill-pay spread, which covers recruiting, credentialing, and malpractice insurance costs before anything reaches EBITDA. Staffing is mostly an undifferentiated service. Hundreds of agencies compete to place the same nurses, so spreads stay thin and independent agencies typically earn EBITDA margins between 6–12%, with Ingenovis peaking at a ~12% margin in 2022 [2][3]. A natural aspect of this business is that clinicians are only paid while on assignment. A staffed professional without a placement costs almost nothing, and 80–90% of the cost base is variable [3]. A drop in volume is manageable, because the costs walk out the door with the clinicians. A bill rate cut is worse, since every lost dollar comes out of the thin spread on the hours still worked. Bill rates are set by how badly hospitals need staff, so price and volume move together. In a shortage, hospitals post more orders at rates that can double within months [1] [4]. Once hospitals rebuild their own staff, both fall away, and revenue swings much harder than the underlying demand for care, which will become important later on. 

Ingenovis reaches this market through eight brands, each kept as a separate name because each sells a different kind of staffing. Together they generated $960mm of revenue in the twelve months through September 2025, roughly a 2.4% share of the $39bn US healthcare staffing market and a top-eight position among more than 800 agencies [3][5]. The brands separate into four segments, explained below in order of importance.

The travel nursing complex is the largest revenue driver, and comprises two brands, Trustaff and Fastaff. Trustaff supplies traditional 13-week assignments into emergency, intensive care, and pediatric units, and generates about one-third of total revenue. On the other hand, Fastaff supplies rapid-response staffing, deploying nurses within days at premium rates when a hospital faces a sudden gap. The premium from this short-notice work makes up roughly another third of total revenue [3]. Together, growth at these two brands took revenue from $700mm in 2020 to $1.9bn in 2022 [3][6]. 

Physician services is the smallest segment by headcount, but likely the most valuable due to its superior stickiness. The reason is that a doctor generates revenue for a hospital through procedures and admissions, while a nurse is a cost. When hospitals cut agency spend, physician coverage is the last line to go [1]. The VISTA Staffing brand provides locum tenens, which is the physician version of travel nursing where hospitals rent a doctor, often for weeks or months at a time, to cover a vacancy or a leave. VISTA contracts roughly 2,500 doctors across more than 60 specialties each year [7]. Another Ingenovis brand, VitalSolution, goes further: rather than filling a single vacancy, it runs a hospital’s entire cardiology and anesthesiology department under contract, serving rural hospitals that could never recruit a cardiologist themselves [8]. Corazon, a consultancy brand and the third leg of the physician division, advises hospitals on building and accrediting cardiac service lines. Notably, physician demand has held up while nursing collapsed through 2023–2025. As a former director at staffing firm EmployBridge explained to us, the locum tenens business is forecasted to grow 5% in 2026 against 1% for travel nursing, and locum businesses have traded up to 15x EBITDA while nursing staffing companies have traded at 3–4x [1][9]. This gap comes down to substitution. No amount of overtime can produce a spare cardiologist, but a missing nurse is a problem hospitals can solve themselves, which is why nursing demand collapses the moment they catch up [1]. 

The last two segments are smaller and simpler. Allied Health places the workers who are neither doctors nor nurses, such as respiratory therapists and lab technicians, with the HealthCare Support brand placing them in hospitals and insurers, and the Springboard brand training and supplying the technicians who run cardiac catheterization labs [10]. Finally, Labor Disruption accounts for ~7% of revenue and covers hospital strikes [6]. When a hospital’s nurses strike, the wards must stay open, and Ingenovis’s U.S. Nursing brand deploys hundreds of replacement nurses on days’ notice at the highest bill rates in the industry. 

One structural choice separates Ingenovis from its larger peers. Most large hospital systems no longer buy temporary labor from dozens of agencies like Ingenovis one at a time. Instead, they hire a single firm, called a managed service provider (MSP), to run the entire program. The MSP takes every order the hospital posts, fills what it can with its own clinicians, and passes the rest down to a network of subcontractor agencies. Giants such as AMN Healthcare, Medical Solutions, and Aya have built their scale on these programs. Unlike these firms, Ingenovis does not run MSP programs and works one layer down as a tier-one subcontractor, meaning that its nurses get the first call on the overflow orders that AMN and Medical Solutions cannot fill themselves [2][6]. This arrangement gives Ingenovis reach into about 7,500 facility partners across more than 30 states through a handful of relationships with the largest MSPs, and since the company is not obligated to fill every order, it is free to concentrate on the placements it deems worth taking. In exchange, the MSP owns the hospital relationships and charges an administrative fee on every placement, leaving Ingenovis to earn its spread on what remains. 

The trade turns against Ingenovis when demand softens. Orders reach the company only after the MSP’s own clinicians are staffed, so when volumes shrink, the overflow is the first thing to disappear, meaning Ingenovis loses volume before the MSP does. At the same time, because the MSP owns the hospital relationship, it holds the pricing power and can keep or raise its fee on the placements that remain [2]. 

Ultimately, every segment is driven by the thesis that hospitals will pay a premium to fulfill staffing requirements when they cannot staff themselves. This premium is what attracted private equity when the company was assembled in 2021.

That assembly is where the history begins. Ingenovis itself is barely five years old, but the brands underneath it are not. Since 2002, Trustaff had placed traditional travel nurses out of Cincinnati. Fastaff began rapid-response staffing in 1989 and spent three decades building a group of nurses willing to fly on short notice. Its sister company, U.S. Nursing, became the name hospitals called before a strike. 

By late 2020, COVID had transformed the brands’ shared asset, traveling clinicians, into the scarcest resource in American healthcare. Together, the three entered 2021 with ~$700mm in combined revenue, over 1,100 hospitals and MSP customers, and staff spread across more than 30 states, with traditional and fast-response nursing each contributing 44% of the total [6]. While each of these businesses had a share of the same scarce resource, travelling clinicians, they lacked the scale to have a national impact. Combining them would require outside capital.

In early 2021, private equity firms Cornell Capital and Trilantic North America bought and merged all four brands, alongside Stella.ai, an AI-driven staffing marketplace intended to modernize recruiting [11]. The thesis was straightforward: each brand recruited from the same group of clinicians willing to travel, but sold them into different moments of hospital need. Recruiting a nurse, licensing her across states, and credentialing her at each facility was the expensive part of staffing, and under separate owners each brand paid that cost alone. Combined under the newly formed Ingenovis Health, one shared database could move a nurse straight from a 13-week Trustaff assignment into a premium Fastaff deployment or a strike posting, so each nurse recruited stayed billable for more weeks of the year [12]. On top of the shared database, an investment in a unified IT platform was expected to lift EBITDA margins to 14%, above the industry average [6]. 

To finance the buyout, Cornell placed an undrawn $50mm revolver due March 2026 and a $525mm first-lien term loan due March 2028, both priced at L + 4.25 [6][13]. The buyout had a valuation of ~$1.1bn, with pro forma leverage of 5.8x, implying adjusted EBITDA of ~$90mm against $525mm of debt, a margin of roughly 13% on the ~$700mm of combined revenue the brands brought in.

For two more years, the COVID staffing boom worked to Ingenovis’ favor. Bill rates continued to rise throughout 2021, and the US travel nursing market increased by roughly four times between 2019 and 2022 [4]. Bill rates that ran in the $80s per hour before the pandemic spiked past $200, and the number of travelers roughly doubled [1]. 

Taking advantage of the period of growth, Ingenovis carried out a number of acquisitions. In November 2021, it acquired HealthCare Support, a staffing company operating on the allied and payer sides. The purchase was funded with an incremental term loan that brought the first lien term loan to $625mm and the revolver to $70mm [12]. Growth showed up immediately, with 2021 pro forma revenue rising to $1.6bn, more than double the ~$700mm figure just a year earlier, though most of that jump was the market wave just described, with likely some added benefit from the shared recruiting platform. In April 2022, Ingenovis addressed its largest gap, acquiring VISTA Staffing Solutions from Envision Physician Services, the physician staffing arm of KKR’s Envision Healthcare, which we previously covered. For Ingenovis, the deal was its first move into physician staffing and away from the nurse staffing core the platform was assembled around. The purchase took the term loan to $675mm [14]. Finally, in December 2022, the company closed its purchase of Springboard Healthcare, a Phoenix-based cardiac staffing and education firm, financed with an $85mm term loan add-on that brought total term facilities to $760mm [10][14].

By 2022, the company had outgrown the original assumptions behind the buyout.  Revenue reached $1.9bn, with ~$240mm of EBITDA at a ~12% margin, and leverage dropped from 5.8x at close to 3.2x despite the addition of two further term loans [6][15]. However, underneath these figures, the seven staffing brands still operated on separate systems, and consolidating them onto a single platform took much longer than planned, a point we will dive into shortly [12][16].

Although Ingenovis exited 2022 at 3.2x leverage, the roughly $240mm EBITDA backing it was earned at the top of the demand cycle for hospital staffing. Over the next three years, three forces would cut revenue in half. First, hospitals rebuilt their own workforces and the premium to fill staffing requirements disappeared. Second, bill rates fell faster than clinician pay, and the spread Ingenovis earned on each placement shrank with them. Third, a rising rate environment pushed interest past what the business could afford. 

The first cracks appeared in 2023, as the shortage that created the staffing boom finally eased. As a reminder, hospitals pay agency premiums only when they cannot fill shifts themselves, and through 2023 most hospitals regained that ability. Hospital systems raised permanent nurse wages, stretched staff from 36-hour to 48-hour weeks, and filled open shifts from internal labor pools before any agency order went out [1][17]. As hospitals pulled back, order volume and bill rates fell at the same time. Revenue declined from $1.9bn in 2022 to $1.6bn in 2023, while EBITDA margin fell from 12% to 4%, implying EBITDA of roughly $60mm, down from ~$240mm a year earlier [3]. Although liquidity remained strong, with ~$230mm of cash on hand at the end of 2023, leverage also rose from 3.2x to 10.4x in a single year as a result of the EBITDA drop [15][18]. 

Falling volume was only part of the problem, as the orders Ingenovis kept became less profitable too. With hundreds of agencies now chasing a shrinking pool of work, hospitals and their MSPs pushed bill rates down faster than clinician pay fell, and on subcontracted orders the MSP’s administrative fee came out of an already thinner margin [2][17]. As the former EmployBridge director explained to us, hospitals reviewed agency spending line by line, and many adopted labor-management software that filled open shifts from the hospital’s own staff before an order ever reached an agency, replacing the whiteboards and spreadsheets much of the industry still ran on [1]. This shift ran across the industry. Between 2022 and 2025, US healthcare staffing revenue shrank by nearly half, and travel nursing by roughly 70% [4]. Ingenovis was no different. Revenue fell to $900mm in 2024, less than half the 2022 peak, and the term loan, which by then had amortized to ~$725mm, traded in the mid 70s by 2024 [3][17] [19]. 

The last driver was the balance sheet itself. At the 2021 close, with LIBOR near zero, the L + 4.25% pricing implied interest of roughly $25mm on the $525mm term loan [13]. Ingenovis’s acquisitions then grew the term facilities to $760mm, sized against peak EBITDA of ~$240mm. By 2024, interest expense nearly tripled to $70mm as the company’s all-in rate effectively reached ~10% against ~$725mm still outstanding, while EBITDA fell to just ~$20mm, the result of a 2.3% margin on $900mm of revenue [3]. 

With interest costs of roughly $70mm against $20mm of EBITDA, Ingenovis was quickly burning cash.  Cash, which stood at $229mm as recently as September 2023, fell to $82mm by June 2024 and $63mm by September 2024 [17][18][20]. By then, the revolver had also exhausted much of its availability since the company could not pass its 7.5x 1L net leverage covenant  [20]. With the revolver maturing in March 2026 and the term loan in March 2028, the company was on pace to reach both with almost nothing left. 

Management spent two years addressing these issues, first from the operating side, and then the financing side. The attempts are worth walking through, because their failure decided the shape of the eventual deal. 

The earnings push came first. A cost program designed with Bain was implemented in late 2023, saving $60mm that year and another $25mm by October 2024, while the platform consolidation promised at the time of the 2021 buyout finally finished in mid-2024 [16][17][20]. Still, the results fell well short of the 2021 underwriting. Against the 14% EBITDA margin the buyout had promised, Ingenovis earned 3.8% in 2023 and less in the years after [3][6]. In response, management pushed the mix toward locum tenens, where margins were stronger [20], and in November 2024 the board replaced CEO Bart Valdez with Benjamin Mirtes, the CFO who had helped assemble the platform [5]. 

The start of 2025 brought unexpected help. Following nurse strikes in California and Oregon, Ingenovis’s U.S. Nursing brand was able to work at the highest billing rates in the industry, bringing revenue to ~$1.1bn and cash to $84mm by March [15]. However, this relief was short-lived once the strike came to an end, and the company’s leverage ratio rose back up to 14.3x by September 2025, with cash falling to $52mm [3][21]. 

The second path, refinancing, required a lender willing to provide it, and by 2025 none existed. At 30 cents, the market valued the $725mm term loan near $220mm, an implied enterprise value that left the equity far out of the money. Against that financial and business profile, no lender was willing to refinance. An asset sale offered no way out either. The physician business was the only piece buyers would pay well for, but it was the same piece supporting the loan’s value, so a sale would have raised cash for the company while leaving lenders with weaker collateral behind their claim. While the sponsors could have written an equity check if they truly believed in the business, using equity dollars outside of restructuring negotiations was clearly out of the picture considering the gravity of the situation and high probability that any dollar they put in would have likely resulted in a direct gift to the lenders.

This left restructuring as the last path. For Ingenovis, Chapter 11 would have solved problems the company did not have. Bankruptcy is useful for handling multi-tranche capital structures or shedding leases, none of which Ingenovis had. Its capital structure held a single class of first-lien lenders and an out-of-the-money sponsor. A filing would have consumed cash the company did not have and signaled distress to the hospitals and clinicians it needed to retain. A private deal with its lenders was the cheaper and quieter route. 

Lenders recognized this early on, and a group holding the term loan engaged Gibson Dunn in November 2024 [19]. By January 13, 2025, roughly 80% of the loan had signed a co-op agreement [22]. Houlihan Lokey joined as the group’s banker, while the company retained Perella Weinberg and Davis Polk [23]. When the revolver reached its March 2026 maturity, Ingenovis and its lenders extended it in increments, first to April and then to June [21][24]. 

While not the best solution overall, bankruptcy still had one use left, forcing holdouts into a deal. By late April, supporting lenders held 73% of the loans, with a steering committee holding over two-thirds [25]. In response to any lender who refused to sign, the company prepared a prepackaged Chapter 11, sending a clear message to the last 27% to either take the deal outside of court or push the same exchange through a courtroom, where months of professional fees would reduce everyone’s recovery, including the holdouts. By then, every conventional exit was closed, and the only remaining path was a deal between the company, its sponsors, and its lenders.